Safety and Immunogenicity of Novartis Meningococcal B Vaccine When Administered to Immunocompromised Children and Adolescents Compared to Healthy Subjects.
Clinical trial NCT02141516 · COMPLETED
Trial details
- NCT number
- NCT02141516
- Sponsor
- Novartis
- Status
- COMPLETED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2014-05-01
- Primary completion
- 2015-03-01
- Enrollment
- 239
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.